How Ajovy Works: The Short Answer

Ajovy (Fremanezumab-vfrm) works by blocking a protein called CGRP (calcitonin gene-related peptide) that plays a key role in triggering migraine attacks — essentially intercepting the migraine signal before it can cause pain.

If that sentence answers your question, great. But if you want to understand why that matters and how it actually works in your body, keep reading. We'll explain it in plain English — no medical degree required.

What Ajovy Does in Your Body

The Migraine Problem: Too Much CGRP

To understand how Ajovy works, you first need to understand what causes a migraine at the biological level.

During a migraine, your trigeminal nerve — a major nerve in your head and face — releases large amounts of a protein called CGRP. This protein does several things that make you feel terrible:

• It dilates blood vessels around your brain, increasing blood flow and causing throbbing pain
• It triggers inflammation in the tissues surrounding your brain
• It makes your pain-sensing nerves more sensitive, so normal stimuli (like light or sound) become excruciating

People who get frequent migraines tend to have higher levels of CGRP in their blood, even between attacks. Their system is essentially primed for migraines all the time.

How Ajovy Stops the Cycle

Think of CGRP as a key and the CGRP receptor (on your nerve and blood vessel cells) as a lock. When the key fits into the lock, it triggers a migraine cascade — vessel dilation, inflammation, pain.

Ajovy is a monoclonal antibody — a lab-made protein designed to act like a bodyguard. It circulates in your bloodstream and grabs onto CGRP molecules before they can reach the receptor. It literally wraps around the CGRP protein and neutralizes it.

Here's the analogy: imagine CGRP molecules are tennis balls being thrown at a target (the receptor). Ajovy acts like a net that catches the tennis balls mid-air before they can hit the target. No ball hits the target, no migraine gets triggered.

Importantly, Ajovy targets the CGRP protein itself — not the receptor. This is a subtle but meaningful distinction from some other migraine medications (more on that below).

How Long Does Ajovy Take to Work?

Ajovy doesn't work like a pain reliever that you feel within an hour. Because it's a preventive treatment, it works over time by gradually reducing the CGRP levels in your system.

Here's a general timeline:

• First month — Some patients notice a reduction in migraine frequency within the first few weeks. In clinical trials, patients saw a measurable decrease in monthly migraine days by the end of month one.
• Months 2 to 3 — The full effect typically becomes apparent by the end of the third month. This is when your doctor will usually assess whether the medication is working well enough to continue.
• Ongoing — With continued use, many patients experience sustained reduction in both migraine frequency and severity.

If you don't notice improvement after 3 months, your doctor may consider adjusting your treatment plan — either changing the dosing schedule or trying a different medication.

How Long Does Ajovy Last?

Ajovy has a long half-life, which is one of the reasons it can be dosed either monthly or quarterly:

• Monthly dose (225 mg) — Provides continuous CGRP blockade throughout the month. The antibody remains active in your system for approximately 31 days.
• Quarterly dose (675 mg) — The larger dose (three 225 mg injections given at once) provides enough antibody to maintain CGRP blockade for approximately 3 months.

The long duration of action is a major advantage for patients who want fewer injection days. You're covered for weeks or months from a single dosing session, compared to daily medications that require constant adherence.

What Makes Ajovy Different from Similar Medications?

Ajovy is one of several CGRP-targeting medications, but they don't all work the same way. Here's how they compare:

Ajovy vs. Aimovig (Erenumab)

This is the biggest mechanistic difference among the CGRP drugs. Ajovy targets the CGRP protein itself, while Aimovig blocks the CGRP receptor. Think of it this way:

• Ajovy catches the tennis ball (CGRP) before it reaches the target
• Aimovig puts a shield over the target (receptor) so the ball can't hit it

Both approaches reduce migraine frequency, but they work at different points in the cascade. Some patients who don't respond to one mechanism may respond to the other.

Ajovy vs. Emgality (Galcanezumab)

Emgality works the same way as Ajovy — both bind directly to the CGRP protein. The main differences are practical:

• Emgality requires a loading dose (240 mg the first month, then 120 mg monthly)
• Ajovy offers both monthly (225 mg) and quarterly (675 mg) dosing options — Emgality is monthly only for migraine prevention
• Emgality is also approved for episodic cluster headache, while Ajovy is not

Ajovy vs. Vyepti (Eptinezumab)

Vyepti also targets the CGRP protein, but it's delivered as an IV infusion in a healthcare setting rather than a self-administered injection at home. Vyepti is given quarterly, similar to Ajovy's quarterly option, but requires a trip to a clinic or infusion center.

Ajovy vs. Qulipta (Atogepant)

Qulipta takes a completely different approach — it's a daily oral tablet that blocks the CGRP receptor (similar to Aimovig's mechanism, but in pill form). It's the best option for patients who want to avoid injections entirely, but it requires daily adherence.

For a full comparison of these options, see our guide to alternatives to Ajovy.

Why CGRP Inhibitors Were a Breakthrough

Before CGRP inhibitors like Ajovy came along, migraine prevention relied on medications that were developed for other conditions — blood pressure drugs (Propranolol), seizure medications (Topiramate), and antidepressants (Amitriptyline). These medications help some patients, but they come with side effects unrelated to migraine and aren't always effective.

CGRP inhibitors were the first class of drugs designed specifically for migraine prevention based on the underlying biology. That's why they tend to have fewer unrelated side effects — they target the migraine mechanism directly rather than broadly affecting other body systems.

Final Thoughts

Ajovy works by catching CGRP — a key migraine trigger protein — before it can activate your pain pathways. It's a targeted, specific approach that has helped many patients reduce their migraine days with minimal side effects. Whether you choose monthly or quarterly dosing, the mechanism is the same: neutralize CGRP, prevent the migraine cascade.

If you're curious about side effects, dosing details, or how to save money on Ajovy, we've got guides for those too.

Ready to find Ajovy at a pharmacy near you? Check availability on Medfinder.